Philip Ashton-Rickardt
Chief Tech/Sci/R&D Officer at SIGILON THERAPEUTICS, INC.
Net worth: - $ as of 2023-07-30
Profile
Philip Ashton-Rickardt was the founder of Smith Therapeutics, Inc. (founded in 2017), where he held the titles of President, CEO, Secretary & Director until 2019.
He is currently the Chief Scientific Officer at Sigilon Therapeutics, Inc. (since 2021).
Previously, he worked as the Chairman of Immunology at Imperial College London, Senior Vice President of Immunology at AZTherapies, Inc. (2019-2021), and Associate Professor at The University of Chicago (1995-2006).
Dr. Ashton-Rickardt obtained his doctorate degree from The University of Edinburgh and his undergraduate degree from King's College London.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2023-08-10 | 0 ( -.--% ) | - $ | 2023-07-30 |
Philip Ashton-Rickardt active positions
| Companies | Position | Start |
|---|---|---|
| SIGILON THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2021-06-13 |
Former positions of Philip Ashton-Rickardt
| Companies | Position | End |
|---|---|---|
AZTherapies, Inc.
 AZTherapies, Inc. Pharmaceuticals: MajorHealth Technology AZTherapies, Inc. engages in the development of therapeutics for Alzheimer’s disease and ischemic stroke treatments. Its product pipelines include ALZT-OP1, ALZT-OP2, AZHALER-D, and ALZT-QoL. The company was founded by David R. Elmaleh in 2011 and is headquartered in Boston, MA. | Corporate Officer/Principal | 2021-05-31 |
Smith Therapeutics, Inc.
 Smith Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Smith Therapeutics, Inc. operates as a biopharmaceutical firm which treats neurodegenerative disease. The company was founded by Philip Ashton-Rickardt in 2017 and is headquartered in Chestnut, MA. | Founder | 2019-10-30 |
| The University of Chicago | Corporate Officer/Principal | 2006-05-31 |
| Imperial College London | Corporate Officer/Principal | - |
Training of Philip Ashton-Rickardt
| The University of Edinburgh | Doctorate Degree |
| King's College London | Undergraduate Degree |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| SIGILON THERAPEUTICS, INC. | Health Technology |
| Private companies | 2 |
|---|---|
AZTherapies, Inc.
AZTherapies, Inc. Pharmaceuticals: MajorHealth Technology AZTherapies, Inc. engages in the development of therapeutics for Alzheimer’s disease and ischemic stroke treatments. Its product pipelines include ALZT-OP1, ALZT-OP2, AZHALER-D, and ALZT-QoL. The company was founded by David R. Elmaleh in 2011 and is headquartered in Boston, MA. | Health Technology |
Smith Therapeutics, Inc.
Smith Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Smith Therapeutics, Inc. operates as a biopharmaceutical firm which treats neurodegenerative disease. The company was founded by Philip Ashton-Rickardt in 2017 and is headquartered in Chestnut, MA. | Health Technology |
- Stock Market
- Insiders
- Philip Ashton-Rickardt
